目的分析氯吡格雷联合溶栓治疗急性ST段抬高心肌梗死的安全性。方法对2016年1-12月的心肌梗死患者进行筛选,选择146例急性ST段抬高心肌梗死患者,按照治疗方法分为联合组、对照组,对比治疗安全性差异。结果两组血管再通率分别94.52%与75.35%,两组治疗后肌酸激酶分别(195.49±62.03)与(354.84±100.46),差异明显(P<0.05)。结论急性ST段抬高心肌梗死加用氯吡格雷疗效、安全性更高,临床应用价值高。 Objective To analyze the safety of clopidogrel combined with thrombolysis in the treatment of acute ST-segment elevation myocardial infarction. Methods From January to December, 2016, patients with myocardial infarction were screened and 146 patients with acute ST-segment elevation myocardial infarction were selected. The patients were divided into combined group and control group according to the treatment method, and the safety of treatment was compared. Results The recanalization rates of the two groups were 94.52% and 75.35%, respectively. The difference of creatine kinase in two groups after treatment was (195.49 ± 62.03) and (354.84 ± 100.46), respectively (P <0.05). Conclusion Acute ST-elevation myocardial infarction combined with clopidogrel efficacy, higher safety, high clinical value.